Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?